Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational H9N2 vaccine GSK2654911A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo |
| Group B | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo |
| Group C | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo |
| Group D | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo |
| Group E | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654909A and placebo |
| Group F | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 5 |
| Group G | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 6 |
| Group H | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 7 |
| Group I | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 8 |
| Group J | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654909A |
| Placebo Group | PLACEBO_COMPARATOR | Subjects will receive Placebo |
| Name | Type | Description |
|---|---|---|
| Investigational H9N2 vaccine GSK2654911A | BIOLOGICAL | 2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm. |
| Investigational H9N2 vaccine GSK2654909A | BIOLOGICAL | 2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm. |
| Placebo | BIOLOGICAL | 1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm. |
Inclusion Criteria: * Male or female adults from 18 to 64 years of age (inclusive) at time of first study vaccination. * Written informed consent obtained from the subject. * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Healthy subjects as esta...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
GSK2654911A is an investigational vaccine developed by GSK plc for influenza, specifically the H9N2 strain. It is a vaccine modality in Phase 1 clinical development. It is not approved and remains under study for the prevention of influenza.
GSK2654911A is being studied for use against influenza, with a focus on the H9N2 influenza strain. It is an investigational vaccine and is not approved for any indication. Its development is in Phase 1.
GSK2654911A is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program evaluating this investigational influenza vaccine.
GSK2654911A is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulatory authority. The Phase 1 program has completed.
GSK2654911A has been evaluated in one Phase 1 trial, NCT01659086, titled a study to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccines GSK2654911A and GSK2654909A in adults 18 to 64 years of age. The trial is completed, enrolled 422 participants, was randomized, double-blind, and placebo-controlled, and took place in the United States and Canada.